Baxter International has received FDA approval to expand the use of Clinolipid, a lipid emulsion, to include pediatric patients, including preterm and term neonates. Clinolipid is a mixed oil emulsion that provides calories and essential fatty acids through intravenous nutrition when oral or enteral nutrition is not feasible.
Parenteral nutrition is crucial in managing malnutrition and reducing its risk. In the US, approximately 40% of patients receiving parenteral nutrition are under 18 years of age. Intravenous lipid emulsions (ILEs) provide essential nutrients for these patients.
Clinolipid is a mixed ILE with a unique composition. It contains the lowest soybean oil (20%) and highest olive oil (80%) among ILEs available in the US. This composition has been proven safe and effective for neonatal and pediatric patients.
With over 150 million doses administered globally, Clinolipid has demonstrated its effectiveness as a source of energy and essential fatty acids for growth and development. It helps support:
• Brain development
• Growth and weight gain
• Immune function
• Inflammatory response
Clinolipid is available for order in the US. Its expanded indication enhances flexibility for clinicians in choosing the most suitable product for their patients. Baxter’s commitment to addressing the unique nutritional needs of pediatric patients through innovative therapies is evident in this approval.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
